The discovery of mutations that contribute to movement disorders has facilitated the identification of converging pathways and novel therapeutic targets. Successful translation of these research findings into clinical practice will require identification of early markers of disease progression, and recent research indicates that progress is being made in this area.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dorsey, E. R. et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384–386 (2007).
Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52 (2011).
Kiskinis, E. & Eggan, K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120, 51–59 (2011).
Vilarino-Guell, C. et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162–167 (2011).
Zimprich, A. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168–175 (2011).
Kumar, K. W. et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol. (in press).
Lill, C. M. & Bertram, L. Complex genetics of neurodegenerative diseases. Semin. Neurol. (in press).
Yanamandra, K. et al. α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6, e18513 (2011).
LeWitt, P. A. et al. AAV2–GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309–319 (2011).
Acknowledgements
C. Klein is funded by a career development award from the Hermann and Lilly Schilling Foundation. D. Krainc is supported by the National Institute of Neurological Disorders and Stroke and the CHDI Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Klein, C., Krainc, D. Translating new research findings into clinical practice. Nat Rev Neurol 8, 65–66 (2012). https://doi.org/10.1038/nrneurol.2011.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.212
